Too old for transplantation: Think again

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The role of high-dose therapy in the management of multiple myeloma in patients older than 65 years has, to date, been uncertain. The current article establishes both survival benefit and improved response duration in patients up to the age of 70 years with multiple myeloma.

Original languageEnglish (US)
Pages (from-to)3000-3001
Number of pages2
JournalBlood
Volume104
Issue number10
DOIs
StatePublished - Nov 15 2004

Fingerprint

Multiple Myeloma
Transplantation
Survival
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Too old for transplantation : Think again. / Gertz, Morie.

In: Blood, Vol. 104, No. 10, 15.11.2004, p. 3000-3001.

Research output: Contribution to journalReview article

Gertz, Morie. / Too old for transplantation : Think again. In: Blood. 2004 ; Vol. 104, No. 10. pp. 3000-3001.
@article{aa1f8a307e6d43c38b8f8646a69910fb,
title = "Too old for transplantation: Think again",
abstract = "The role of high-dose therapy in the management of multiple myeloma in patients older than 65 years has, to date, been uncertain. The current article establishes both survival benefit and improved response duration in patients up to the age of 70 years with multiple myeloma.",
author = "Morie Gertz",
year = "2004",
month = "11",
day = "15",
doi = "10.1182/blood-2004-08-3183",
language = "English (US)",
volume = "104",
pages = "3000--3001",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Too old for transplantation

T2 - Think again

AU - Gertz, Morie

PY - 2004/11/15

Y1 - 2004/11/15

N2 - The role of high-dose therapy in the management of multiple myeloma in patients older than 65 years has, to date, been uncertain. The current article establishes both survival benefit and improved response duration in patients up to the age of 70 years with multiple myeloma.

AB - The role of high-dose therapy in the management of multiple myeloma in patients older than 65 years has, to date, been uncertain. The current article establishes both survival benefit and improved response duration in patients up to the age of 70 years with multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=8644227881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8644227881&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-08-3183

DO - 10.1182/blood-2004-08-3183

M3 - Review article

AN - SCOPUS:8644227881

VL - 104

SP - 3000

EP - 3001

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -